PD 325901

Drug Profile

PD 325901

Alternative Names: PD-0325901; PD-325901

Latest Information Update: 09 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer AstraZeneca; BIOENSIS; Pfizer; SpringWorks Therapeutics; University of Alabama at Birmingham; University of Oxford
  • Class Aniline compounds; Anti-inflammatories; Antineoplastics; Benzamides; Immunotherapies; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors; Mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neurofibromatoses
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Neurofibromatoses
  • Preclinical Cervical cancer; Chronic obstructive pulmonary disease
  • No development reported Colorectal cancer
  • Discontinued Breast cancer; Cancer; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 05 Nov 2018 PD 325901 receives Orphan Drug status for Neurofibromatosis in USA
  • 05 Sep 2018 PD 325901 is available for licensing as of 05 Sep 2018. http://www.springworkstx.com/
  • 05 Sep 2018 SpringWorks Therapeutics and BeiGene enters into global clinical collaboration for Solid Tumors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top